Immatics (IMTX) Other Accumulated Expenses (2019 - 2026)
Immatics (IMTX) posted Other Accumulated Expenses of $6.5 million for Q4 2025, up 21.45% sequentially from $5.4 million in Q3 2025, and down 10.25% YoY from $7.3 million in Q4 2024.
Analysis
Immatics (IMTX) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Immatics has reported Other Accumulated Expenses for 7 years, with the latest figure at $6.5 million in Q4 2025.
- Quarterly Other Accumulated Expenses fell 10.25% year-over-year to $6.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.5 million (down 10.25% YoY) and the FY2025 annual result came in at $6.3 million, down 13.99% from the prior year.
- Other Accumulated Expenses improved to $6.5 million in Q4 2025 per IMTX's latest filing, from $5.4 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $16.6 million in Q3 2024 and troughed at $1.7 million in Q1 2021.
- A 5-year average of $6.7 million and a median of $7.1 million in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2023: Other Accumulated Expenses sank 85.38% in 2021, then soared 377.4% in 2023.
- Over 5 years, Other Accumulated Expenses stood at $2.9 million in 2021, then surged by 227.31% to $9.6 million in 2022, then increased by 5.26% to $10.1 million in 2023, then retreated by 27.7% to $7.3 million in 2024, then fell by 10.25% to $6.5 million in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $6.5 million, $5.4 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.58 Mn |
| Mar 31, 2026 | 6.04 Mn |
| Dec 31, 2025 | 6.53 Mn |
| Sep 30, 2025 | 5.37 Mn |
| Jun 30, 2025 | 7.65 Mn |
| Mar 31, 2025 | 6.99 Mn |
| Dec 31, 2024 | 7.27 Mn |
| Sep 30, 2024 | 16.64 Mn |
| Jun 30, 2024 | 10.79 Mn |
| Mar 31, 2024 | 10.42 Mn |
| Dec 31, 2023 | 10.06 Mn |
| Sep 30, 2023 | 8.29 Mn |
| Jun 30, 2023 | 8.63 Mn |
| Mar 31, 2023 | 8.57 Mn |
| Dec 31, 2022 | 9.56 Mn |
| Sep 30, 2022 | 4.40 Mn |
| Jun 30, 2022 | 3.11 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 1.73 Mn |